We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.
- Authors
Kareem, Syeda Saba; Viswanathan, Neena; Sahebjam, Solmaz; Tran, Nam D; Gatewood, Tyra; Tobon, Katherine; Baz, Rachid; Piña, Yolanda; Shain, Kenneth H; Mokhtari, Sepideh
- Abstract
Leukoencephalopathy in the setting of multiple myeloma (MM) is a rare demyelinating condition, with few reported cases in literature. Daratumumab is a CD38 targeted monoclonal antibody that has been widely used for the management of MM. In the absence of central nervous system (CNS) disease, many medication-induced leukoencephalopathy cases reported with MM, including daratumumab-induced, are associated with progressive multifocal leukoencephalopathy (PML) and John Cunningham (JC) virus. Currently, there are no reported cases of daratumumab-induced leukoencephalopathy among patients without CNS involvement or PML. We discuss 2 patients who developed leukoencephalopathy while receiving daratumumab-based therapy without evidence of PML or CNS disease. Both patients had baseline MRIs without significant white matter changes before daratumumab-based therapy. Patients began experiencing neurological deficits about 6 to 8 months after daratumumab-based therapy initiation. One patient passed away before being assessed for improvement of symptoms with daratumumab cessation. The second patient had some stabilization of symptoms after cessation; however, the leukoencephalopathy remained irreversible. As the class of anti-CD38 monoclonal antibodies expands in MM therapy, we highlight a potential treatment complication and the importance of detecting leukoencephalopathy early among patients receiving anti-CD38 therapy. We recommend vigilant monitoring of any new or worsening neurological symptoms to avoid serious complications of irreversible leukoencephalopathy.
- Subjects
MULTIPLE myeloma; PROGRESSIVE multifocal leukoencephalopathy; LEUKOENCEPHALOPATHIES; JOHN Cunningham virus; MONOCLONAL antibodies; CENTRAL nervous system; PLASMA cell diseases
- Publication
OncoTargets & Therapy, 2022, Vol 15, p953
- ISSN
1178-6930
- Publication type
Case Study
- DOI
10.2147/OTT.S365657